Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 110

1.

Ionic Liquid Forms of the Antimalarial Lumefantrine in Combination with LFCS Type IIIB Lipid-Based Formulations Preferentially Increase Lipid Solubility, In Vitro Solubilization Behavior and In Vivo Exposure.

Tay E, Nguyen TH, Ford L, Williams HD, Benameur H, Scammells PJ, Porter CJH.

Pharmaceutics. 2019 Dec 22;12(1). pii: E17. doi: 10.3390/pharmaceutics12010017.

2.

Unlocking the full potential of lipid-based formulations using lipophilic salt/ionic liquid forms.

Williams HD, Ford L, Igonin A, Shan Z, Botti P, Morgen MM, Hu G, Pouton CW, Scammells PJ, Porter CJH, Benameur H.

Adv Drug Deliv Rev. 2019 Mar 1;142:75-90. doi: 10.1016/j.addr.2019.05.008. Epub 2019 May 29. Review.

PMID:
31150666
3.

In vitro and in vivo properties of the bovine antimicrobial peptide, Bactenecin 5.

Price RL, Bugeon L, Mostowy S, Makendi C, Wren BW, Williams HD, Willcocks SJ.

PLoS One. 2019 Jan 9;14(1):e0210508. doi: 10.1371/journal.pone.0210508. eCollection 2019.

4.

Enhancing the Oral Absorption of Kinase Inhibitors Using Lipophilic Salts and Lipid-Based Formulations.

Williams HD, Ford L, Han S, Tangso KJ, Lim S, Shackleford DM, Vodak DT, Benameur H, Pouton CW, Scammells PJ, Porter CJH.

Mol Pharm. 2018 Dec 3;15(12):5678-5696. doi: 10.1021/acs.molpharmaceut.8b00858. Epub 2018 Nov 13.

5.

Cyclic di-adenosine monophosphate (c-di-AMP) is required for osmotic regulation in Staphylococcus aureus but dispensable for viability in anaerobic conditions.

Zeden MS, Schuster CF, Bowman L, Zhong Q, Williams HD, Gründling A.

J Biol Chem. 2018 Mar 2;293(9):3180-3200. doi: 10.1074/jbc.M117.818716. Epub 2018 Jan 11.

6.

Ionic Liquid Forms of Weakly Acidic Drugs in Oral Lipid Formulations: Preparation, Characterization, in Vitro Digestion, and in Vivo Absorption Studies.

Sahbaz Y, Nguyen TH, Ford L, McEvoy CL, Williams HD, Scammells PJ, Porter CJH.

Mol Pharm. 2017 Nov 6;14(11):3669-3683. doi: 10.1021/acs.molpharmaceut.7b00442. Epub 2017 Oct 10.

PMID:
28954512
7.

Current and future therapies for Pseudomonas aeruginosa infection in patients with cystic fibrosis.

Smith WD, Bardin E, Cameron L, Edmondson CL, Farrant KV, Martin I, Murphy RA, Soren O, Turnbull AR, Wierre-Gore N, Alton EW, Bundy JG, Bush A, Connett GJ, Faust SN, Filloux A, Freemont PS, Jones AL, Takats Z, Webb JS, Williams HD, Davies JC.

FEMS Microbiol Lett. 2017 Aug 1;364(14). doi: 10.1093/femsle/fnx121. Review.

PMID:
28854668
8.

Transformation of Biopharmaceutical Classification System Class I and III Drugs Into Ionic Liquids and Lipophilic Salts for Enhanced Developability Using Lipid Formulations.

Williams HD, Ford L, Lim S, Han S, Baumann J, Sullivan H, Vodak D, Igonin A, Benameur H, Pouton CW, Scammells PJ, Porter CJH.

J Pharm Sci. 2018 Jan;107(1):203-216. doi: 10.1016/j.xphs.2017.05.019. Epub 2017 May 23.

PMID:
28549907
9.

Pseudomonas aeruginosa infection in cystic fibrosis: pathophysiological mechanisms and therapeutic approaches.

Lund-Palau H, Turnbull AR, Bush A, Bardin E, Cameron L, Soren O, Wierre-Gore N, Alton EW, Bundy JG, Connett G, Faust SN, Filloux A, Freemont P, Jones A, Khoo V, Morales S, Murphy R, Pabary R, Simbo A, Schelenz S, Takats Z, Webb J, Williams HD, Davies JC.

Expert Rev Respir Med. 2016 Jun;10(6):685-97. doi: 10.1080/17476348.2016.1177460. Epub 2016 May 13. Review.

10.

50years of oral lipid-based formulations: Provenance, progress and future perspectives.

Feeney OM, Crum MF, McEvoy CL, Trevaskis NL, Williams HD, Pouton CW, Charman WN, Bergström CAS, Porter CJH.

Adv Drug Deliv Rev. 2016 Jun 1;101:167-194. doi: 10.1016/j.addr.2016.04.007. Epub 2016 Apr 16. Review.

PMID:
27089810
11.

A new in vitro lipid digestion - in vivo absorption model to evaluate the mechanisms of drug absorption from lipid-based formulations.

Crum MF, Trevaskis NL, Williams HD, Pouton CW, Porter CJ.

Pharm Res. 2016 Apr;33(4):970-82. doi: 10.1007/s11095-015-1843-7. Epub 2015 Dec 24.

PMID:
26703975
12.

Influence of the Crc regulator on the hierarchical use of carbon sources from a complete medium in Pseudomonas.

La Rosa R, Behrends V, Williams HD, Bundy JG, Rojo F.

Environ Microbiol. 2016 Mar;18(3):807-18. doi: 10.1111/1462-2920.13126. Epub 2016 Jan 18.

13.

Transformation of poorly water-soluble drugs into lipophilic ionic liquids enhances oral drug exposure from lipid based formulations.

Sahbaz Y, Williams HD, Nguyen TH, Saunders J, Ford L, Charman SA, Scammells PJ, Porter CJ.

Mol Pharm. 2015 Jun 1;12(6):1980-91. doi: 10.1021/mp500790t. Epub 2015 May 5.

PMID:
25905624
14.

Toward the establishment of standardized in vitro tests for lipid-based formulations. 5. Lipolysis of representative formulations by gastric lipase.

Bakala-N'Goma JC, Williams HD, Sassene PJ, Kleberg K, Calderone M, Jannin V, Igonin A, Partheil A, Marchaud D, Jule E, Vertommen J, Maio M, Blundell R, Benameur H, Müllertz A, Pouton CW, Porter CJ, Carrière F.

Pharm Res. 2015 Apr;32(4):1279-87. doi: 10.1007/s11095-014-1532-y. Epub 2014 Oct 7.

PMID:
25288015
15.

Toward the establishment of standardized in vitro tests for lipid-based formulations, part 6: effects of varying pancreatin and calcium levels.

Sassene P, Kleberg K, Williams HD, Bakala-N'Goma JC, Carrière F, Calderone M, Jannin V, Igonin A, Partheil A, Marchaud D, Jule E, Vertommen J, Maio M, Blundell R, Benameur H, Porter CJ, Pouton CW, Müllertz A.

AAPS J. 2014 Nov;16(6):1344-57. doi: 10.1208/s12248-014-9672-x. Epub 2014 Oct 2.

16.

An in vitro digestion test that reflects rat intestinal conditions to probe the importance of formulation digestion vs first pass metabolism in Danazol bioavailability from lipid based formulations.

Anby MU, Nguyen TH, Yeap YY, Feeney OM, Williams HD, Benameur H, Pouton CW, Porter CJ.

Mol Pharm. 2014 Nov 3;11(11):4069-83. doi: 10.1021/mp500197b. Epub 2014 Sep 29.

PMID:
25265395
17.

Cyanide levels found in infected cystic fibrosis sputum inhibit airway ciliary function.

Nair C, Shoemark A, Chan M, Ollosson S, Dixon M, Hogg C, Alton EW, Davies JC, Williams HD.

Eur Respir J. 2014 Nov;44(5):1253-61. doi: 10.1183/09031936.00097014. Epub 2014 Sep 3.

18.

'Stealth' lipid-based formulations: poly(ethylene glycol)-mediated digestion inhibition improves oral bioavailability of a model poorly water soluble drug.

Feeney OM, Williams HD, Pouton CW, Porter CJ.

J Control Release. 2014 Oct 28;192:219-27. doi: 10.1016/j.jconrel.2014.07.037. Epub 2014 Jul 22.

PMID:
25058571
19.

An in vivo crosslinking system for identifying mycobacterial protein-protein interactions.

Lougheed KE, Bennett MH, Williams HD.

J Microbiol Methods. 2014 Oct;105:67-71. doi: 10.1016/j.mimet.2014.07.012. Epub 2014 Jul 14.

20.

Digestion of phospholipids after secretion of bile into the duodenum changes the phase behavior of bile components.

Birru WA, Warren DB, Ibrahim A, Williams HD, Benameur H, Porter CJ, Chalmers DK, Pouton CW.

Mol Pharm. 2014 Aug 4;11(8):2825-34. doi: 10.1021/mp500193g. Epub 2014 Jul 16.

PMID:
24987935
21.

Toward the establishment of standardized in vitro tests for lipid-based formulations, part 4: proposing a new lipid formulation performance classification system.

Williams HD, Sassene P, Kleberg K, Calderone M, Igonin A, Jule E, Vertommen J, Blundell R, Benameur H, Müllertz A, Porter CJ, Pouton CW; Communicated on Behalf of the LFCS Consortium.

J Pharm Sci. 2014 Aug;103(8):2441-55. doi: 10.1002/jps.24067. Epub 2014 Jul 1.

PMID:
24985238
22.

The mucoid switch in Pseudomonas aeruginosa represses quorum sensing systems and leads to complex changes to stationary phase virulence factor regulation.

Ryall B, Carrara M, Zlosnik JE, Behrends V, Lee X, Wong Z, Lougheed KE, Williams HD.

PLoS One. 2014 May 22;9(5):e96166. doi: 10.1371/journal.pone.0096166. eCollection 2014.

23.

Cyanide measurements in bacterial culture and sputum.

Nair CG, Ryall B, Williams HD.

Methods Mol Biol. 2014;1149:325-36. doi: 10.1007/978-1-4939-0473-0_27.

PMID:
24818917
24.

Metabolic footprinting: extracellular metabolomic analysis.

Behrends V, Williams HD, Bundy JG.

Methods Mol Biol. 2014;1149:281-92. doi: 10.1007/978-1-4939-0473-0_23.

PMID:
24818913
25.

Lipid-based formulations solidified via adsorption onto the mesoporous carrier Neusilin® US2: effect of drug type and formulation composition on in vitro pharmaceutical performance.

Williams HD, Van Speybroeck M, Augustijns P, Porter CJ.

J Pharm Sci. 2014 Jun;103(6):1734-46. doi: 10.1002/jps.23970. Epub 2014 Apr 16.

PMID:
24740767
26.

A novel cyanide-inducible gene cluster helps protect Pseudomonas aeruginosa from cyanide.

Frangipani E, Pérez-Martínez I, Williams HD, Cherbuin G, Haas D.

Environ Microbiol Rep. 2014 Feb;6(1):28-34. doi: 10.1111/1758-2229.12105. Epub 2013 Oct 17.

PMID:
24596260
27.

Non-linear increases in danazol exposure with dose in older vs. younger beagle dogs: the potential role of differences in bile salt concentration, thermodynamic activity, and formulation digestion.

Anby MU, Williams HD, Feeney O, Edwards GA, Benameur H, Pouton CW, Porter CJ.

Pharm Res. 2014 Jun;31(6):1536-52. doi: 10.1007/s11095-013-1260-8. Epub 2014 Jan 30.

PMID:
24477676
29.

Ionic liquids provide unique opportunities for oral drug delivery: structure optimization and in vivo evidence of utility.

Williams HD, Sahbaz Y, Ford L, Nguyen TH, Scammells PJ, Porter CJ.

Chem Commun (Camb). 2014 Feb 18;50(14):1688-90. doi: 10.1039/c3cc48650h.

PMID:
24394756
30.

Recent advances in lipid-based formulation technology.

Porter CJ, Williams HD, Trevaskis NL.

Pharm Res. 2013 Dec;30(12):2971-5. doi: 10.1007/s11095-013-1229-7. Epub 2013 Oct 26. No abstract available.

PMID:
24158727
31.

Lipid-based formulations and drug supersaturation: harnessing the unique benefits of the lipid digestion/absorption pathway.

Williams HD, Trevaskis NL, Yeap YY, Anby MU, Pouton CW, Porter CJ.

Pharm Res. 2013 Dec;30(12):2976-92. doi: 10.1007/s11095-013-1126-0. Epub 2013 Jul 4. Review.

PMID:
23824582
32.

In vitro assessment of drug-free and fenofibrate-containing lipid formulations using dispersion and digestion testing gives detailed insights into the likely fate of formulations in the intestine.

Devraj R, Williams HD, Warren DB, Mohsin K, Porter CJ, Pouton CW.

Eur J Pharm Sci. 2013 Jul 16;49(4):748-60. doi: 10.1016/j.ejps.2013.04.036. Epub 2013 May 16.

PMID:
23684915
33.

Toward the establishment of standardized in vitro tests for lipid-based formulations, part 3: understanding supersaturation versus precipitation potential during the in vitro digestion of type I, II, IIIA, IIIB and IV lipid-based formulations.

Williams HD, Sassene P, Kleberg K, Calderone M, Igonin A, Jule E, Vertommen J, Blundell R, Benameur H, Müllertz A, Pouton CW, Porter CJ; LFCS Consortium.

Pharm Res. 2013 Dec;30(12):3059-76. doi: 10.1007/s11095-013-1038-z. Epub 2013 May 10.

PMID:
23661145
34.

Metabolite profiling to characterize disease-related bacteria: gluconate excretion by Pseudomonas aeruginosa mutants and clinical isolates from cystic fibrosis patients.

Behrends V, Bell TJ, Liebeke M, Cordes-Blauert A, Ashraf SN, Nair C, Zlosnik JE, Williams HD, Bundy JG.

J Biol Chem. 2013 May 24;288(21):15098-109. doi: 10.1074/jbc.M112.442814. Epub 2013 Apr 9.

35.

Strategies to address low drug solubility in discovery and development.

Williams HD, Trevaskis NL, Charman SA, Shanker RM, Charman WN, Pouton CW, Porter CJ.

Pharmacol Rev. 2013 Jan;65(1):315-499. Review.

PMID:
23383426
36.

Direct assessment of metabolite utilization by Pseudomonas aeruginosa during growth on artificial sputum medium.

Behrends V, Geier B, Williams HD, Bundy JG.

Appl Environ Microbiol. 2013 Apr;79(7):2467-70. doi: 10.1128/AEM.03609-12. Epub 2013 Jan 25.

37.

Sub-lethal concentrations of antibiotics increase mutation frequency in the cystic fibrosis pathogen Pseudomonas aeruginosa.

Nair CG, Chao C, Ryall B, Williams HD.

Lett Appl Microbiol. 2013 Feb;56(2):149-54. doi: 10.1111/lam.12032. Epub 2013 Jan 7.

38.

In vitro digestion testing of lipid-based delivery systems: calcium ions combine with fatty acids liberated from triglyceride rich lipid solutions to form soaps and reduce the solubilization capacity of colloidal digestion products.

Devraj R, Williams HD, Warren DB, Mullertz A, Porter CJ, Pouton CW.

Int J Pharm. 2013 Jan 30;441(1-2):323-33. doi: 10.1016/j.ijpharm.2012.11.024. Epub 2012 Nov 23.

PMID:
23178598
39.

Toward the establishment of standardized in vitro tests for lipid-based formulations. 2. The effect of bile salt concentration and drug loading on the performance of type I, II, IIIA, IIIB, and IV formulations during in vitro digestion.

Williams HD, Anby MU, Sassene P, Kleberg K, Bakala-N'Goma JC, Calderone M, Jannin V, Igonin A, Partheil A, Marchaud D, Jule E, Vertommen J, Maio M, Blundell R, Benameur H, Carrière F, Müllertz A, Pouton CW, Porter CJ.

Mol Pharm. 2012 Nov 5;9(11):3286-300. doi: 10.1021/mp300331z. Epub 2012 Oct 22.

PMID:
23030411
40.

Metabolic adaptations of Pseudomonas aeruginosa during cystic fibrosis chronic lung infections.

Behrends V, Ryall B, Zlosnik JE, Speert DP, Bundy JG, Williams HD.

Environ Microbiol. 2013 Feb;15(2):398-408. doi: 10.1111/j.1462-2920.2012.02840.x. Epub 2012 Aug 8.

PMID:
22882524
41.

Incomplete desorption of liquid excipients reduces the in vitro and in vivo performance of self-emulsifying drug delivery systems solidified by adsorption onto an inorganic mesoporous carrier.

Van Speybroeck M, Williams HD, Nguyen TH, Anby MU, Porter CJ, Augustijns P.

Mol Pharm. 2012 Sep 4;9(9):2750-60. doi: 10.1021/mp300298z. Epub 2012 Aug 7.

PMID:
22870936
42.

Lipid digestion as a trigger for supersaturation: evaluation of the impact of supersaturation stabilization on the in vitro and in vivo performance of self-emulsifying drug delivery systems.

Anby MU, Williams HD, McIntosh M, Benameur H, Edwards GA, Pouton CW, Porter CJ.

Mol Pharm. 2012 Jul 2;9(7):2063-79. doi: 10.1021/mp300164u. Epub 2012 Jun 15.

PMID:
22656917
43.

Toward the establishment of standardized in vitro tests for lipid-based formulations, part 1: method parameterization and comparison of in vitro digestion profiles across a range of representative formulations.

Williams HD, Sassene P, Kleberg K, Bakala-N'Goma JC, Calderone M, Jannin V, Igonin A, Partheil A, Marchaud D, Jule E, Vertommen J, Maio M, Blundell R, Benameur H, Carrière F, Müllertz A, Porter CJ, Pouton CW.

J Pharm Sci. 2012 Sep;101(9):3360-80. doi: 10.1002/jps.23205. Epub 2012 May 29.

PMID:
22644939
44.

The dormancy regulator DosR controls ribosome stability in hypoxic mycobacteria.

Trauner A, Lougheed KE, Bennett MH, Hingley-Wilson SM, Williams HD.

J Biol Chem. 2012 Jul 6;287(28):24053-63. doi: 10.1074/jbc.M112.364851. Epub 2012 Apr 27.

45.

Basic science for the chest physician: Pseudomonas aeruginosa and the cystic fibrosis airway.

Williams HD, Davies JC.

Thorax. 2012 May;67(5):465-7. doi: 10.1136/thoraxjnl-2011-201498. Epub 2012 Mar 1. Review. No abstract available.

PMID:
22382597
46.

Drug release from HPMC matrices in milk and fat-rich emulsions.

Williams HD, Nott KP, Barrett DA, Ward R, Hardy IJ, Melia CD.

J Pharm Sci. 2011 Nov;100(11):4823-35. doi: 10.1002/jps.22689. Epub 2011 Jul 15.

PMID:
21766309
47.

Differences in strategies to combat osmotic stress in Burkholderia cenocepacia elucidated by NMR-based metabolic profiling.

Behrends V, Bundy JG, Williams HD.

Lett Appl Microbiol. 2011 Jun;52(6):619-25. doi: 10.1111/j.1472-765X.2011.03050.x. Epub 2011 Apr 21.

48.

Isolation of bacterial ribosomes with monolith chromatography.

Trauner A, Bennett MH, Williams HD.

PLoS One. 2011 Feb 4;6(2):e16273. doi: 10.1371/journal.pone.0016273.

49.

Designing HPMC matrices with improved resistance to dissolved sugar.

Williams HD, Ward R, Culy A, Hardy IJ, Melia CD.

Int J Pharm. 2010 Nov 30;401(1-2):51-9. doi: 10.1016/j.ijpharm.2010.09.009. Epub 2010 Sep 19.

PMID:
20858538
50.

The effect of sucrose and salts in combination on the drug release behaviour of an HPMC matrix.

Williams HD, Ward R, Hardy IJ, Melia CD.

Eur J Pharm Biopharm. 2010 Nov;76(3):433-6. doi: 10.1016/j.ejpb.2010.09.001. Epub 2010 Sep 15.

PMID:
20837144

Supplemental Content

Loading ...
Support Center